Effect of gender differences on early and mid-term clinical outcome after percutaneous or surgical coronary revascularisation in patients with multivessel coronary artery disease: Insights from ARTS I and ARTS II

Sex‐specific outcomes following revascularization with zotarolimus‐eluting stents: Comparison of angiographic and late‐term clinical results

“…However, in both studies, the relative reduction between DES and BMS for angiographic and clinical restenosis was independent of sex status, and 1-year adjusted clinical outcomes among men and women did not statistically differ. These results are consistent with observational registries [8,27] and indirect comparative trials [28] evaluating in-hospital and late-term sex-specific outcomes with paclitaxel-and sirolimus-eluting stent treatment in more complex lesion and patient indications. In comparison, recent combined analysis of men and women treated with everolimus-and paclitaxeleluting stents (n ¼ 314 women) reported significantly higher 1-year repeat revascularization in women, although this difference could not be fully explained following adjustment for higher clinical and angiographic risk [16].…”

Gender-Based Issues in Interventional Cardiology: a Consensus Statement from the Women in Innovations (WIN) Initiative

“…This occurred despite the fact that women tended to be older and have more co-morbidities such as diabetes and hypertension [11,12]. At 3 years in the ARTS II study of 607 patients (23% female), there was no significant difference in the rate of MACCE (19.8% in men vs. 17.6% in women, relative risk 1.12 [95% CI 0.75-1.68], P ¼ 0.63) [14]. Compared to those treated with BMS, women treated with Taxus stents had a 46% relative reduction in TLR (12.0% vs. 22.2%, P < 0.001), with comparable rates of death, MI, and stent thrombosis (ST) through 5 years between the two groups.…”

Sex Differences in the Drug-Eluting Stent Era

“…Results of the Stefanini et al study (20) and others (13)(14)(15)(16)(17)(18)(19) suggest that DES have leveled the playing field between men and women undergoing PCI. Many studies have shown that acute angiographic success, late restenosis, and clinical outcomes are now similar between men and women, despite advanced age and more comorbidities in the latter.…”

“…A national registry reported that sex was no longer predictive of major adverse cardiac events in the era of stenting (12). Drug-eluting stents (DES) seem to be equally effective at reducing restenosis and improving outcomes in both men and women (13)(14)(15)(16)(17)(18)(19). In fact, secondgeneration DES might be particularly well-suited for the small tortuous coronary arteries found in some women, given their lower profile, more enhanced deliverability, and thinner strut designs.…”